Nyxoah Information

Nyxoah (Euronext Brussels/Nasdaq: NYXH) is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and the mission to make sleep simple. Nyxoah’s lead solution is the Genio system, a patient-centered hypoglossal neurostimulation therapy for OSA, including: • Bilateral stimulation • An upgradable external wearable • No implanted battery, thus no additional procedures to replace the battery • MR conditional labeling for full-body 1.5T and 3T MRI scans* The Genio system received its European CE Mark in 2019 and Nyxoah subsequently completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. In 2021, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients in Europe, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use. *For MRI guidelines, visit geniosleep.com/MRI